49 results on '"Kaitu'u-Lino, Tu'uhevaha"'
Search Results
2. Can single-cell and spatial omics unravel the pathophysiology of pre-eclampsia?
3. Cell surface associated protein mucin 15 (MUC15) is elevated in preeclampsia
4. Placental DAAM2 is unaltered in preeclampsia, but upregulated by treatment with proton pump inhibitors
5. The effect of metformin on cardiovascular markers in female mice consuming a high fat diet
6. LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast
7. Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia
8. Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction
9. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) is reduced with preeclampsia and small for gestational aged fetuses
10. Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia
11. Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome
12. EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia
13. Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia
14. Loss of Akt increases soluble endoglin release from endothelial cells but not placenta
15. Upregulation of placental Ski-like proto-oncogene in preterm preeclampsia: potential target for preeclampsia treatment?
16. Characterising side population genes in placentas from patients with preeclampsia and/or fetal growth restriction.
17. In vitro investigation into the regulation and function of SPINT1, a biomarker for fetal growth restriction
18. The Brain Natriuretic Peptide (BNP) system is expressed in the placenta and vasculature in preeclampsia: potential implications for novel therapeutic strategies
19. Therapeutic intervention to alleviate long-term cardiovascular risk following preeclampsia
20. A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin
21. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin
22. Circulating serine peptidase inhibitor Kunitz type 1 (SPINT1) in the second trimester is reduced among pregnancies that end in low birthweight neonates: cohort study of 2006 pregnancies
23. Circulating Activin A is elevated at 36 weeks’ gestation preceding a diagnosis of preeclampsia
24. Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeks’ gestation
25. ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia
26. sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies?
27. P-065. New human models of preeclampsia; offering physiologically relevant assays for the development of therapeutics to ameliorate preeclamptic vascular dysfunction
28. P-009. Associations between circulating sFlt-1 and PlGF and preeclampsia with severe maternal complications, or eclampsia
29. O-004. Circulating SIGLEC6 is deranged in preeclampsia and may be a biomarker of disease severity
30. Peptides do not prevent cleavage of endoglin to produce soluble endoglin
31. 286. Endothelin-1 is elevated prior to the development of term preeclampsia and is exacerbated in established severe early onset preeclampsia
32. 200. Clinical trial of metformin to treat preterm preeclampsia: pharmacokinetics and biomarker studies
33. 190. Combination sulfasalazine and metformin are additive in reducing placental secretion of antiangiogenic factor sFlt
34. 82. Disulfiram inhibits placental sFLT-1 secretion
35. 291. MicroRNAs in maternal circulation as predictors of preeclampsia at term
36. 293. Preclinical assessment of new generation antiplatelet therapies to prevent preeclampsia
37. 296. Loss of Placental NR4A2 may contribute to the pathogeneisis of pre-eclampsia
38. 131. EGFR and the mitochondria; two parallel pathways regulating sFLT-1 secretion from placenta
39. Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage
40. MMP-14 Is Expressed in Preeclamptic Placentas and Mediates Release of Soluble Endoglin
41. 43 New generation antiplatelet therapies to prevent preeclampsia: Endothelial dysfunction, anti-angiogenic factors
42. 4 Epidermal growth factor receptor positively regulates sFlt1 secretion
43. [44-OR]: Statins reduce soluble Flt1, and quench endothelial dysfunction in primary human tissues, but increase soluble endoglin release
44. [28-OR]: The newly described primate and placental specific sFlt1 isoform – e15a is biologically active and antagonises VEGF
45. [6-OR]: Proton pump inhibitors for treatment of preeclampsia
46. [273-POS]: Sulfasalazine reduces the toxins of preeclampsia soluble Flt1 and soluble endoglin and quenches endothelial dysfunction in primary human tissues: A novel potential therapeutic
47. [261-POS]: Heme oxygenase-1 is not reduced in pre-eclampsia and does not regulate sFlt-1 or soluble endoglin production
48. Combination methotrexate and gefitinib (EGFR inhibitor) as a novel therapeutic to medically treat ectopic pregnancies: preclinical studies and human trials
49. Generation and testing of an ELISA that detects the newly discovered primate and placental specific sFlt variant (sFlt1-e15a)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.